
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics reported a 17% year-over-year increase in the sale of nanochannel array flowcells in 2Q25, reaching 7,233 units compared to 6,165 in 2Q24, and an additional 7% growth in sales during 3Q25. The company achieved an 11% year-over-year growth in combined revenue from consumables, software, and remaining services in 2Q25, with consumables and software alone rising by 16%. Furthermore, Bionano's expectations for new optical genome mapping (OGM) installations in FY2025 have increased to a range of 20-25 units, reflecting robust momentum in both established and expanding international markets.
Bears say
Bionano Genomics faces significant risks that could hinder its financial performance, including lower than projected market uptake and utilization of its products and systems. Additionally, the company's reliance on securing further capital to fund operations raises concerns about its financial stability, alongside the inherent dilution risk associated with such capital raises. Furthermore, based on comparative valuation metrics, the projected financial outlook suggests a price objective of approximately $11, which implies potential challenges in sustaining investor confidence given these adverse factors.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares